Serosurvey of Crimean–Congo Hemorrhagic Fever Virus in Cattle, Mali, West Africa

Maiga, Ousmane; Sas, Miriam; Rosenke, Kyle; Kamissoko, Badian; Mertens, Marc; Sogoba, Nafomon; Traoré, Abdallah; Sangaré, Modibo; Niang, Mamadou; Schwan, Tom G.; Maiga, Hamidou Moussa; Traorè, Sékou F.; Feldmann, Heinz; Safronetz, David; Groschup, Martin H.

doi:10.4269/ajtmh.16-0818

Cited by 27 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CCHF cases were also reported in Senegal which borders Mauritana to the south [21,22]. In Mali, eastwards of Mauritania, no human cases of CCHF have been reported, but serological data [23] and virus detection in ticks [24] have also proven a CCHFV circulation in Mali. However, CCHFV monitoring in ticks (especially of the genus Hyalomma) has not yet been conducted systematically in this West African region.…”

Section: Discussionmentioning

confidence: 99%

Detection of Crimean-Congo hemorrhagic fever virus (CCHFV) in Hyalomma ticks collected from Mauritanian livestock

Schulz

Barry²,

Stoek

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Crimean-Congo hemorrhagic fever virus (CCHFV) belongs to the Nairovididae family in the Orthonairovirus genus and is an emerging tick-borne virus. It is endemic in most parts of Africa, Asia, as well as southern Europe, and can cause severe hemorrhagic symptoms in humans with high fatality rates (5-30 %). Methods: Hyalomma ticks were collected from four different livestock herds (cattle and camel) from Mauritania in 2018. The tick species was determined morphologically and confirmed on a molecular level by using cytochrome oxidase 1 gene marker (CO1). For the detection of CCHFV, ticks were tested individually with a one-step multiplex real-time RT-qPCR. Subsequently, the S-segment of all positive samples were sequenced to determine the CCHFV genotype.Results: Overall, 39 of 1,523 ticks (2.56 %) collected from 63 cattle and 28 camels were tested positive for CCHFV. Three Hyalomma (H.) species were identified. The highest prevalence of CCHFV was found in Hyalomma rufipes (5.67 %; 16/282), followed by H. dromedarii (1.89 %; 23/1,214) and H. impeltatum (0 %; 0/21). Positive ticks were found on only 6 out of 91 host animals. Sequence analysis of the positive samples revealed the presence of two different CCHFV lineages (Africa I and Africa III). Conclusions: This study reveals a CCHFV prevalence of 2.56 % in Hyalomma ticks collected from camels and cattle in Mauritania. The true prevalence of unfed ticks may however be lower since a considerable number of ticks may have been passively infected during the ingestion of the blood meal by co-feeding or viremia of the host. The study shows that tick control measures should be implemented, especially in the examined areas.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of Crimean-Congo hemorrhagic fever virus (CCHFV) in Hyalomma ticks collected from Mauritanian livestock

Schulz

Barry²,

Stoek

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…La prévalence sérologique globale observée est de 9%, un résultat nettement inférieur à celui obtenu chez les bovins au Mali (66%) et en Mauritanie (67%) (Maiga et al, 2017 ;Sas et al 2017).…”

Section: Discussionunclassified

“…Cette différence pourrait être due au fait que dans ces deux communes proches l'une de l'autre, les éleveurs partagent les mêmes pâturages, les tiques ont été assez abondantes, et surtout que celles-ci servent à la fois de vecteur mais aussi de réservoir pour le virus de la FHCC (Whitehouse, 2004). Par ailleurs, la disparité des prévalences selon des endroits peut être due à la densité des animaux dans la zone comme en témoignent les résultats obtenus par Maiga et al (2017). En plus, la possible transmission horizontale et verticale du virus chez les tiques est un facteur contribuant au maintien durable de la maladie (Gargili et al, 2017).…”

Section: Discussionunclassified

Epidémiologie de la fièvre Hémorragique de Crimée-Congo (FHCC) chez les bovins dans le département de Boboye au Niger

Maïna¹,

Ibrahim²,

Alassane³

et al. 2020

Int. J. Bio. Chem. Sci

View full text Add to dashboard Cite

La distribution et la dynamique des populations des tiques est un élément clé dans la connaissance des maladies transmises par ces vecteurs. C’est ainsi que cette étude a été conduite afin de mieux connaître l’épidémiologie de la Fièvre Hémorragique de Crimée-Congo (FHCC) dans les 8 communes du département de Boboye au Niger, où 355 sérums de bovins ont été collectés. En plus des sérums, des tiques ont été collectées sur 144 bovins, soit 18 par commune. Les sérums ont été soumis à un test ELISA (Enzyme Linked Immunosorbent Assay) indirect pour la détection d’anticorps anti-FHCC. Soixante-douze (72) éleveurs ont été interviewés sur leur connaissance de l’écologie des tiques, vecteurs du virus de la FHCC. Les résultats de l’enquête ont révélé que les éleveurs n’ont pas recours aux acaricides et que, dans leur majorité (55/72 soit 76,4 %), ils pratiquent la transhumance. L’étude a permis l’identification de 1342 tiques réparties en trois genres : Hyalomma (91,7%), Amblyomma (5,7%) et Rhipicephalus (Boophilus) (2,6%). La séroprévalence globale a été de 9,1±0,03%. Les communes de Harikanassou et Kiota ont été celles où les fortes prévalences ont été observées de 26,7 ± 12,9% et 22,5 ±12,9%. Le virus de la FHCC est en circulation chez la population animale, alors des investigations doivent être faites chez la population humaine.Mots clés : Anticorps anti-FHCC, Enzyme Linked Immunosorbent Assay Indirecte, Prévalence, Sérums, Tiques. English Title: Crimean-Congo Hemorrhagic Fever (CCHF) ’s Epidemiology in cattle in Boboye’s department of Niger Republic To understand disease transmission by ticks, knowledge of population dynamics and distribution of these vectors are essentials. To sought that, the epidemiology of Crimean-Congo Hemorrhagic Fever (CCHF) in Niger Republic was studied by sampling 355 bovines (sera and ticks) in eight (8) local governments in Boboye’s department. Eighteen (18) bovines were sampled for ticks collection per local government making them a total of 144 bovine. Indirect ELISA test (enzyme-linked immunosorbent assay) was used to detect anti- CCHF antibodies. Seventy-two (72) farmers were surveyed on their knowledge on ticks’ ecology, main vectors of CCHF virus. The results revealed that farmers are not using acaricides, and their majority (55/72 thus 76.4%) practice Transhumance. The study allowed the identification of 1342 ticks distributed in 3 genus: Hyalomma (91.7%), Amblyomma (5.7%) and Rhipicephalus (Boophilus) (2.6%). The global seroprevalence against CCHF was (9.1 ± 0.03) %. Harikanassou and Kiota were the most affected local governments with respectively (26.7±12.9) % and (22.5±12,9) % prevalence. CCHV virus is circulating in animal population, so investigations must be made in human population. Keywords: Anti-CCHF antibodies, Indirect Enzyme Linked Immunosorbent Assay, Prevalence, Sera, Ticks.

show abstract

“…African countries from which CCHF has been reported include Burkina Faso, Central Africa Republic, Democratic Republic of Congo, Egypt, Kenya, Mauritania, Namibia, Nigeria, South Africa, Senegal, Sudan, Tanzania, and Uganda 1,[7][8][9][10][11][12][13][14][15][16] and countries yet to report CCHF but with evidence of viral circulation either from serological surveys or CCHFV isolation from ticks include Algeria, Benin, Cameroon, Equatorial Guinea, Ethiopia, Ghana, Guinea, Mali, Madagascar, Morocco, Mozambique, Niger, Somalia, Tunisia, and Zimbabwe. 1,[17][18][19][20][21][22][23][24][25][26][27][28][29][30] The presence of CCHFV in Somalia was suggested after evidence of the CCHFV in Hyalomma ticks obtained from Somali cattle and sheep exported to the United Arab Emirates. 28 In the Middle East, the disease has been described in Iran, Iraq, Saudi Arabia, Oman, and the United Arab Emirates.…”

Section: Introductionmentioning

confidence: 99%

Crimean–Congo Hemorrhagic Fever Virus: Advances in Vaccine Development

Tipih

Burt

2020

BioResearch Open Access

View full text Add to dashboard Cite

Crimean-Congo hemorrhagic fever (CCHF) is a severe human disease with mortality rates of up to 30%. The disease is widespread in Africa, Asia, the Middle East and Eastern Europe. The last few years have seen disease emergence in Spain for the first time and disease re-emergence in other regions of the world after periods of inactivity. Factors, such as climate change, movement of infected ticks, animals, and changes in human activity, are likely to broaden endemic foci. There are therefore concerns that CCHF might emerge in currently nonendemic regions. The absence of approved vaccines or therapies heightens these concerns; thus Crimean-Congo hemorrhagic fever virus (CCHFV) is listed by the World Health Organization as a priority organism. However, the current sporadic nature of CCHF cases may call for targeted vaccination of risk groups as opposed to mass vaccinations. CCHF vaccine development has accelerated in recent years, partly because of the discovery of CCHF animal models. In this review, we discuss CCHF risk groups who are most likely to benefit from vaccine development, the merits and demerits of available CCHF animal models, and the various approaches which have been explored for CCHF vaccine development. Lastly, we present concluding remarks and research areas which can be further explored to enhance the available CCHFV vaccine data.

show abstract

Serosurvey of Crimean–Congo Hemorrhagic Fever Virus in Cattle, Mali, West Africa

Cited by 27 publications

References 31 publications

Detection of Crimean-Congo hemorrhagic fever virus (CCHFV) in Hyalomma ticks collected from Mauritanian livestock

Detection of Crimean-Congo hemorrhagic fever virus (CCHFV) in Hyalomma ticks collected from Mauritanian livestock

Epidémiologie de la fièvre Hémorragique de Crimée-Congo (FHCC) chez les bovins dans le département de Boboye au Niger

Crimean–Congo Hemorrhagic Fever Virus: Advances in Vaccine Development

Contact Info

Product

Resources

About